Table 2.
Association between serum concentration of IGF-1 and breast cancer by SNPs of genes regulating energy homeostasis, the Breast Cancer Health Disparities Study.
| IGF-1 association with premenopausal breast cancer | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variables | OR | 95% CI | P value | |||||||||
| IGF-1 T1 | 1.00 | |||||||||||
| IGF-1 T2 | 1.34 | 0.87, 2.04 | 0.18 | |||||||||
| IGF-1 T3 | 2.79 | 1.88, 4.13 | < 0.0001 | |||||||||
| Interaction Co-dominant models | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IGF-1*SNP Pinteraction | ||||||||||||
| SNP | Variables | OR | 95% CI | P value | OR | 95% CI | P value | OR | 95% CI | P value | Raw | Adjusteda |
| ADIPOQ | 0 = GG; Cases = 223; Controls = 338 | 1 = GA; Cases = 26; Controls = 49 | 2 = AA; Cases = 0; Controls = 2 | |||||||||
| rs17366568 | IGF-1 T1 | 1.00 | 1.00 | |||||||||
| 0 = GG/1 = GA 2 = AA | IGF-1 T2 | 0.96 | 0.57, 1.63 | 0.89 | 0.14 | 0.01, 1.54 | 0.11 | |||||
| n = 561/n = 75/n = 2 | IGF-1 T3 | 1.62 | 0.93, 2.82 | 0.09 | 0.09 | 0.01, 0.91 | 0.04 | 0.098 | 0.944 | |||
| GHRL | 0 = TT; Cases = 155; Controls = 234 | 1 = TC; Cases = 83; Controls = 126 | 2 = CC; Cases = 11; Controls = 29 | |||||||||
| rs27647 | IGF-1 T1 | 1.00 | 1.00 | |||||||||
| 0 = TT /1 = TC 2 = CC | IGF-1 T2 | 0.96 | 0.50, 1.84 | 0.89 | 0.70 | 0.29, 1.71 | 0.44 | |||||
| n = 389/n = 209/n = 40 | IGF-1 T3 | 1. 75 | 0.90, 3.42 | 0.10 | 1.13 | 0.45, 2.86 | 0.79 | 0.039 | 0.312 | |||
| LEPR | 0 = TT; Cases = 90; Controls = 140 | 1 = TG; Cases = 119; Controls = 193 | 2 = GG; Cases = 40; Controls = 56 | |||||||||
| rs970468 | IGF-1 T1 | 1.00 | 1.00 | 1.00 | ||||||||
| 0 = TT /1 = TG/2 = GG | IGF-1 T2 | 0.71 | 0.30, 1.69 | 0.44 | 0.95 | 0.45, 1.97 | 0.88 | 1.24 | 0.29, 5.29 | 0.77 | ||
| n = 230/n = 312/n = 96 | IGF-1 T3 | 1.52 | 0.61, 3.79 | 0.37 | 1.42 | 0.67, 3.02 | 0.36 | 0.59 | 0.13, 2.77 | 0.50 | 0.089 | 0.587 |
| 0 = GG; Cases = 201; Controls = 303 | 1 = GA; Cases = 42; Controls = 83 | 2 = AA; Cases = 6; Controls = 3 | ||||||||||
| rs12059300 | IGF-1 T1 | 1.00 | 1.00 | |||||||||
| 0 = GG/1 = GA 2 = AA | IGF-1 T2 | 0.83 | 0.46, 1.49 | 0.54 | 0.96 | 0.31, 3.04 | 0.95 | |||||
| n = 504/n = 125/n = 9 | IGF-1 T3 | 1.48 | 0.82, 2.68 | 0.19 | 0.61 | 0.15, 2.44 | 0.49 | 0.003 | 0.069 | |||
| MBOAT4 | 0 = AA; Cases = 53; Controls = 99 | 1 = AG; Cases = 120; Controls = 176 | 2 = GG; Cases = 76; Controls = 114 | |||||||||
| rs13272159 | IGF-1 T1 | 1.00 | 1.00 | 1.00 | 1.00 | |||||||
| 0 = AA/1 = AG/2 = GG | IGF-1 T2 | 3.92 | 0.91, 16.97 | 0.07 | 0.60 | 0.27, 1.32 | 0.60 | 0.89 | 0.37, 2.18 | 0.80 | ||
| n = 152/n = 296/n = 190 | IGF-1 T3 | 7.16 | 1.64, 31.25 | 0.009 | 1.29 | 0.57, 2.94 | 1.29 | 0.60 | 0.23, 1.59 | 0.31 | 0.027 | 0.027 |
| NPY | 0 = AA; Cases = 214; Controls = 332 | 1 = AG; Cases = 32; Controls = 53 | 2 = GG; Cases = 3; Controls = 4 | |||||||||
| rs16131 | IGF-1 T1 | 1.00 | 1.00 | |||||||||
| 0 = AA/1 = AG 2 = GG | IGF-1 T2 | 1.14 | 0.66, 2.00 | 0.64 | 0.13 | 0.03, 0.71 | 0.02 | |||||
| n = 546 /n = 85/n = 7 | IGF-1 T3 | 1.77 | 1.00, 3.14 | 0.05 | 0.28 | 0.05, 1.64 | 0.16 | 0.004 | 0.012 | |||
| POMC | 0 = GG; Cases = 209; Controls = 340 | 1 = GA; Cases = 39; Controls = 48 | 2 = AA; Cases = 1; Controls = 1 | |||||||||
| rs7565427 | IGF-1T1 | 1.00 | 1.00 | |||||||||
| 0 = GG/1 = GA 2 = AA | IGF-1T2 | 1.20 | 0.70, 2.06 | 0.52 | 0.05 | 0.01, 0.41 | 0.006 | |||||
| n = 549/n = 87/n = 2 | IGF-1T3 | 1.89 | 1.07, 3.35 | 0.03 | 0.05 | 0.01, 0.51 | 0.01 | 0.079 | 0.316 | |||
The model at the top of the table was not adjusted for potential confounders. The rest of the models were adjusted for IGFBP-3 serum concentration (ng/mL), age (years), genetic ancestry (% Indigenous), BMI (Kg/m2), energy intake (Kcal/day), height (cm), age at menarche (years), ever use oral contraceptives (no,yes), parity (nulliparous, 1 or 2, 3 or more), study (4-CBCS, MBCS), first-degree family history of breast cancer (no, yes), ever alcohol consumption (no, yes) and ever cigarette smoking (no, yes). aBenjamini-Hochberg adjusted P values (correction for the number of SNPs tested per gene); a threshold of 0.2 was considered significant.